Study Title

This is a, two-step, cross-over, open-label phase 0 study comparing the therapeutic index of 177Lu-DOTA-JR11 and 177Lu-DOTATOC followed by a single-arm open-label Phase I/II study.

Study Details

Description:

Meningiomas are known to be the most frequent intracranial neoplasms and account for approx. 25-33% of all intracranial tumours.Targeted radionuclide therapy with radiolabelled somatostatin analogues, also called Peptide Receptor Radionuclide Therapy (PRRT), has proven to be an effective treatment in metastatic intestinal neuroendocrine tumours and is currently used in advanced, recurrent or progressive meningiomas with promising results. In this study, the therapeutic index of a standard and newly developed radiolabelled somatostatin antagonist will be evaluated and compared in PRRT. In a second step, safety and efficacy of the latter will be assessed.

Sponsor:

University Hospital, Basel, Switzerland

Contacts:

Damian Wild, Prof. Dr. med.

damian.wild@usb.ch

+41 61 328 6683

Dominik Cordier, PD Dr. med.

dominik.cordier@usb.ch

+41 61 55 65 642

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468